KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to 0.8.

  • Biomarin Pharmaceutical's Equity Ratio rose 66.33% to 0.8 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.8, marking a year-over-year increase of 66.33%. This contributed to the annual value of 0.81 for FY2024, which is 1185.82% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Equity Ratio is 0.8, which was up 66.33% from 0.81 recorded in Q2 2025.
  • Biomarin Pharmaceutical's Equity Ratio's 5-year high stood at 0.81 during Q1 2025, with a 5-year trough of 0.71 in Q4 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median Equity Ratio value was 0.73 (recorded in 2023), while the average stood at 0.75.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Equity Ratio skyrocketed by 1779.71% in 2021, and later tumbled by 64.91% in 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Equity Ratio (Quarter) stood at 0.71 in 2021, then grew by 1.64% to 0.72 in 2022, then rose by 0.23% to 0.72 in 2023, then increased by 11.86% to 0.81 in 2024, then fell by 1.75% to 0.8 in 2025.
  • Its Equity Ratio was 0.8 in Q3 2025, compared to 0.81 in Q2 2025 and 0.81 in Q1 2025.